Xiao Shuai, Shi Yiting, Li Rui
Department of Thoracic Surgery, Ningbo No. 2 Hospital, Ningbo, China.
AME Case Rep. 2025 Jun 19;9:83. doi: 10.21037/acr-24-151. eCollection 2025.
Non-small cell lung cancer accounts for more than 85% of lung malignancies. Preoperative neoadjuvant therapy is considered to be a method that can improve the long-term prognosis of locally advanced non-small cell lung cancer, and radiotherapy and chemotherapy are the main treatment options. With the continuous discovery of different targets, more and more targeted drugs benefit more patients, but there are few reports on the treatment mode of targeted neoadjuvant combined chemotherapy. In this study, we report a case of targeted combination chemotherapy as a new adjuvant option for locally advanced lung adenocarcinoma, with a view to providing more treatment references for similar patients. ROS proto-oncogene 1 () rearrangements are observed in 1-2% of patients with non-small cell lung cancer (NSCLC). It is a clinically rare mutation, and patients with fusions have been shown to be highly sensitive to treatment with crizotinib. However, the efficacy and safety of crizotinib combined with neoadjuvant chemotherapy in patients with locally advanced NSCLC remain to be elucidated.
We report the case of a 49-year-old male who was diagnosed with stage IIIb (N2) lung adenocarcinoma. Next-generation sequencing revealed fusions, and crizotinib was given simultaneously with targeted therapy during neoadjuvant chemotherapy. After 3 cycles of chemotherapy, surgery was performed, and the pathological results revealed major pathological response (MPR). Two years later, local and general examinations revealed no evidence of tumour recurrence.
This study highlights the effective exploration of the combination of targeted therapy and chemotherapy in the neoadjuvant treatment mode of locally advanced non-small cell lung cancer. For patients with sensitive genetic mutations, early use may benefit the patient more, just as the most effective time to use a fire extinguisher is when the flame starts.
非小细胞肺癌占肺部恶性肿瘤的85%以上。术前新辅助治疗被认为是一种可以改善局部晚期非小细胞肺癌长期预后的方法,放疗和化疗是主要的治疗选择。随着不同靶点的不断发现,越来越多的靶向药物使更多患者受益,但关于靶向新辅助联合化疗的治疗模式报道较少。在本研究中,我们报告一例将靶向联合化疗作为局部晚期肺腺癌新辅助治疗选择的病例,以期为类似患者提供更多治疗参考。在1%-2%的非小细胞肺癌(NSCLC)患者中观察到ROS原癌基因1()重排。这是一种临床上罕见的突变,已证明具有融合的患者对克唑替尼治疗高度敏感。然而,克唑替尼联合新辅助化疗在局部晚期NSCLC患者中的疗效和安全性仍有待阐明。
我们报告一例49岁男性患者,诊断为Ⅲb期(N2)肺腺癌。二代测序显示有融合,在新辅助化疗期间给予克唑替尼同时进行靶向治疗。化疗3个周期后进行手术,病理结果显示主要病理缓解(MPR)。两年后,局部和全身检查未发现肿瘤复发迹象。
本研究突出了在局部晚期非小细胞肺癌新辅助治疗模式中对靶向治疗与化疗联合应用的有效探索。对于有敏感基因突变的患者,尽早使用可能使患者受益更多,就像灭火器最有效的使用时间是火焰刚燃起时一样。